PMID- 32018126
OWN - NLM
STAT- MEDLINE
DCOM- 20200324
LR  - 20200324
IS  - 1879-0461 (Electronic)
IS  - 1040-8428 (Linking)
VI  - 147
DP  - 2020 Mar
TI  - Magnitude of benefit of the addition of poly ADP-ribose polymerase (PARP) 
      inhibitors to therapy for malignant tumor: A meta-analysis.
PG  - 102888
LID - S1040-8428(20)30026-3 [pii]
LID - 10.1016/j.critrevonc.2020.102888 [doi]
AB  - BACKGROUND: The purpose of this study was to analyze the efficacy of PARP 
      inhibitor on solid tumors. METHODS: For this study, the following databases were 
      searched for articles published from its inception until July 2019: PubMed, Web 
      of Science, EBSCO, and Cochrane library, of which the main conclusion was the 
      overall survival (OS) and progression-free survival (PFS). RESULTS: We conducted 
      a meta-analysis and the results showed that PARP inhibitor increased the 
      patients' PFS (HR: 0.51, p < 0.001), PFS with BRCA1/2 mutations (HR: 0.32, p < 
      0.001), OS (HR: 0.74, p < 0.001), OS with BRCA1/2 mutations (HR: 0.78, p = 0.03), 
      complete response (CR) (RR: 1.89, p = 0.10), partial response (PR) (RR: 1.34, p = 
      0.01), overall response rate (ORR) (RR: 1.42, p = 0.001) respectively. The main 
      adverse events (AEs) observed were decreased appetite. CONCLUSIONS: PARP 
      inhibitors may prolong survival. PARP inhibitors were more favorable for BRCA1/2 
      mutations in ovarian cancer patients. Additionally, the overall safety factor was 
      controllable.
CI  - Copyright (c) 2020 Elsevier B.V. All rights reserved.
FAU - Gu, Lihu
AU  - Gu L
AD  - Department of General Surgery, HwaMei Hospital, University of Chinese Academy of 
      Sciences, Ningbo, Zhejiang, China. Electronic address: gulihuuyanzhi@126.com.
FAU - Du, Nannan
AU  - Du N
AD  - The Second Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China. Electronic address: 2097815997@qq.com.
FAU - Jin, Qiong
AU  - Jin Q
AD  - Emergency Medical Center, the Second Hospital of Yinzhou, 998 North Qianhe Road, 
      Yinzhou District, Ningbo, Zhejiang, China. Electronic address: 
      yinzhouh219@163.com.
FAU - Li, Shengnan
AU  - Li S
AD  - The Second Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China. Electronic address: 1609132951@qq.com.
FAU - Xie, Laidi
AU  - Xie L
AD  - College of Obstetrics and Gynecology, Zhejiang University School of Medicine, 
      Hangzhou, China. Electronic address: 13588820516@163.com.
FAU - Mo, Jiahang
AU  - Mo J
AD  - The Second Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China. Electronic address: 18267167743@163.com.
FAU - Shen, Zefeng
AU  - Shen Z
AD  - The Second Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China. Electronic address: 291821586@qq.com.
FAU - Mao, Danyi
AU  - Mao D
AD  - Basic Medical College, Zhejiang Chinese Medical University, Hangzhou, Zhejiang, 
      China. Electronic address: danyimao@163.com.
FAU - Ji, Jia
AU  - Ji J
AD  - The Second Clinical Medical College, Zhejiang Chinese Medical University, 
      Hangzhou, Zhejiang, China. Electronic address: 825292263@qq.com.
FAU - Khadaroo, Parikshit Asutosh
AU  - Khadaroo PA
AD  - Monash University School of Medicine, Nursing and Health Sciences, Melbourne, 
      Australia. Electronic address: asutoshkhadaro@hotmail.com.
FAU - Chen, Bangsheng
AU  - Chen B
AD  - Emergency Medical Center, the Second Hospital of Yinzhou, 998 North Qianhe Road, 
      Yinzhou District, Ningbo, Zhejiang, China. Electronic address: 
      Yinzhouno2012@163.com.
LA  - eng
PT  - Journal Article
PT  - Meta-Analysis
PT  - Review
DEP - 20200130
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Antineoplastic Agents)
RN  - 0 (BRCA1 Protein)
RN  - 0 (BRCA2 Protein)
RN  - 0 (Enzyme Inhibitors)
RN  - 0 (Poly(ADP-ribose) Polymerase Inhibitors)
RN  - 20762-30-5 (Adenosine Diphosphate Ribose)
RN  - EC 2.4.2.30 (Poly(ADP-ribose) Polymerases)
SB  - IM
MH  - Adenosine Diphosphate Ribose
MH  - Antineoplastic Agents/*therapeutic use
MH  - BRCA1 Protein/*genetics
MH  - BRCA2 Protein/*genetics
MH  - Enzyme Inhibitors/pharmacology/therapeutic use
MH  - Female
MH  - Humans
MH  - Ovarian Neoplasms/*drug therapy/*genetics/mortality/pathology
MH  - Poly(ADP-ribose) Polymerase Inhibitors/*therapeutic use
MH  - Poly(ADP-ribose) Polymerases
MH  - Prognosis
MH  - Survival
MH  - Treatment Outcome
OTO - NOTNLM
OT  - Adverse events
OT  - BRCA1/2
OT  - Evaluation of solid tumors
OT  - PARP inhibitor
OT  - Survival
COIS- Declaration of Competing Interest The authors declare that they have no conflict 
      of interest.
EDAT- 2020/02/06 06:00
MHDA- 2020/03/25 06:00
CRDT- 2020/02/05 06:00
PHST- 2019/09/24 00:00 [received]
PHST- 2020/01/22 00:00 [revised]
PHST- 2020/01/28 00:00 [accepted]
PHST- 2020/02/06 06:00 [pubmed]
PHST- 2020/03/25 06:00 [medline]
PHST- 2020/02/05 06:00 [entrez]
AID - S1040-8428(20)30026-3 [pii]
AID - 10.1016/j.critrevonc.2020.102888 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2020 Mar;147:102888. doi: 
      10.1016/j.critrevonc.2020.102888. Epub 2020 Jan 30.